Palafox-Romo R, Malagón-Liceaga A, Méndez-Flores S

Language: Spanish
References: 20
Page: 176-181
PDF size: 126.17 Kb.

ABSTRACT

This article reviews the relevance of cutaneous adverse effects associated with immunotherapy using immune checkpoint inhibitors (ICI), such as those targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-l1), and cytotoxic t-lymphocyte antigen 4 (CTLA-4), which have transformed the therapeutic approach to cancer. While these ICI enhance immune responses against malignant cells, they can also induce skin conditions ranging from exanthema to Stevens-Johnson-like reactions. The incidence varies depending on the type of ICI and the treated cancer. The need for meticulous management of these adverse effects is emphasized, proposing guidelines based on severity and highlighting the collaboration between oncologists and dermatologists.

REFERENCES

1. Sakurai K, Niitsuma S, Iizuka A et al., Immune-related adverseevents in various organs caused by immune checkpoint inhibitors,Allergol Int 2022; 71(2):169-78.

2. Li B, Chan HL y Chen P, Immune checkpoint inhibitors: basicsand challenges, Curr Med Chem 2019; 26(17): 3009-25.

3. Carlino MS, Larkin J y Long GV, Immune checkpoint inhibitors inmelanoma, Lancet 2021; 398(10304):1002-14.

4. Wang J, Yang T y Xu J, Therapeutic development of immunecheckpoint inhibitors, Adv Exp Med Biol 2020; 1248:619-49.

5. Ellis SR, Vierra AT, Millsop JW, Lacouture ME y Kiuru M, Dermatologictoxicities to immune checkpoint inhibitor therapy: areview of histopathologic features, J Am Acad Dermatol 2020;83(4):1130-43.

6. Sibaud V, Dermatologic reactions to immune checkpoint inhibitors:skin toxicities and immunotherapy, Am J Clin Dermatol2018; 19(3):345-61.

7. El Osta B, Hu F, Sadek R, Chintalapally R y Tang SC, Not allimmune-checkpoint inhibitors are created equal: meta-analysisand systematic review of immune-related adverse events incancer trials, Crit Rev Oncol Hematol 2017; 119:1-12.

8. Khoja L, Day D, Wei-Wu CT, Siu LL y Hansen AR, Tumour andclass-specific patterns of immune-related adverse events ofimmune checkpoint inhibitors: a systematic review, Ann Oncol2017; 28(10):2377-85.

9. Postow MA, Sidlow R y Hellmann MD, Immune-related adverseevents associated with immune checkpoint blockade, N Engl JMed 2018; 378(2):158-68.

10. Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R y LitvinovIV, Cutaneous immune-related adverse events (iraes) toimmune checkpoint inhibitors: a dermatology perspective onmanagement, J Cutan Med Surg 2021; 25(1):59-76.

11. Watanabe T y Yamaguchi Y, Cutaneous manifestations associatedwith immune checkpoint inhibitors, Front Immunol 2023;14:1071983.

12. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J y Delord JP,Dermatologic complications of anti-pd-1/pd-l1 immune checkpointantibodies, Curr Opin Oncol. 2016; 28(4):254-63.

13. Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, GirardiM et al., Clinical and histologic features of lichenoid mucocutaneouseruptions due to anti-programmed cell death 1 and antiprogrammed cell death ligand 1 immunotherapy, jama Dermatol2016; 152(10):1128-36.

14. Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E,French LE et al., Cytotoxic cutaneous adverse drug reactionsduring anti- pd-1 therapy, Clin Cancer Res 2016; 22(16):4023-9.

15. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G yWeber JS, Nivolumab in resected and unresectable metastaticmelanoma: characteristics of immune-related adverseevents and association with outcomes, Clin Cancer Res 2016;22(4):886-94.

16. Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJet al., Immune-related alopecia (areata and universalis) in cancerpatients receiving immune checkpoint inhibitors, Br J Dermatol2017; 176(6):1649-52.

17. Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione FJr, Sznol M et al., Bullous disorders associated with anti-pd-1and anti-pd-l1 therapy: a retrospective analysis evaluating theclinical and histopathologic features, frequency, and impact oncancer therapy, J Am Acad Dermatol. 2018; 79(6):1081-8.

18. Shi CR, Shaughnessy M, Sehgal K, Clark JR, Reynolds KL, ToyoharaJ et al., Successful rechallenge with pembrolizumab aftercase of progressive immunotherapy-related mucocutaneouseruption (pirme), a Stevens-Johnson syndrome-like reaction, IntJ Dermatol 2023; 62(10):1292-4.

19. Maloney NJ, Ravi V, Cheng K, Bach DQ y Worswick S, Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactionsto checkpoint inhibitors: a systematic review, Int J Dermatol 2020; 59(6):e183-8.

20. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, AdkinsS, Anadkat M et al., Management of immune-related adverseevents in patients treated with immune checkpoint inhibitor therapy:asco guideline update, J Clin Oncol 2021; 39(36):4073-126.